Mostrar el registro sencillo del ítem

dc.contributor.author
Perez Lloret, Santiago  
dc.contributor.author
Rey, María Verónica  
dc.contributor.author
Fabre, Nelly  
dc.contributor.author
Ory, Fabienne  
dc.contributor.author
Spampinato, Umberto  
dc.contributor.author
Brefel Courbon, Christine  
dc.contributor.author
Montastruc, Jean Louis  
dc.contributor.author
Rascol, Olivier  
dc.date.available
2023-05-22T13:05:50Z  
dc.date.issued
2012-11  
dc.identifier.citation
Perez Lloret, Santiago; Rey, María Verónica; Fabre, Nelly; Ory, Fabienne; Spampinato, Umberto; et al.; Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with parkinson disease; Lippincott Williams; Clinical Neuropharmacology; 35; 6; 11-2012; 261-265  
dc.identifier.issn
0362-5664  
dc.identifier.uri
http://hdl.handle.net/11336/198333  
dc.description.abstract
BACKGROUND: Impulse-control disorders (ICDs) occur in patients with Parkinson disease (PD), especially in younger patients on dopamine therapies. OBJECTIVE: To assess the prevalence of ICD symptoms and its pharmacological correlations in a sample of French patients with PD and without PD (poststroke). METHODS: Outpatients with PD and without PD (poststroke) were screened for compulsive behaviors related to hypersexuality, compulsive shopping, pathological gambling, or compulsive eating by means of the Questionnaire for Impulse-Control Disorders-short version. Full medical history and Unified Parkinson's Disease Rating Scale scores were also recorded. Dose of dopamine agonists were converted to defined daily doses (DDDs), according to the World Health Organization Anatomical Therapeutic Chemical classification system classification system. RESULTS: Two hundred three patients with PD and 52 patients without PD were recruited (mean ± SD age, 67 ± 1 vs 69 ± 2, P= 0.4; males: 62% vs 55% P= 0.2). Symptoms of ICDs were reported by 0% of poststroke patients and 25% of the patients with PD (P < 0.001). Hypersexuality was reported by 10% of the patients with PD, compulsive shopping by 6%, pathological gambling by 3%, and compulsive eating by 14%. A logistic regression analysis found that age younger than 68 years (odds ratio [OR], 3.3; 95% confidence interval, 1.6-6.6) and exposure to dopamine agonists (OR, 20.3; 95% confidence interval, 2.7-65.0) or monoaminooxidase-B inhibitor (OR, 3.7; 95% confidence interval, 1.1-12.6) were significant factors associated with increased ICD frequency. Patients with ICD symptoms were exposed to higher dopamine doses than those without them (1.6 ± 0.1 vs 1.0 ± 0.1 daily-defined doses; P < 0.001). A dose-response pharmacodynamic model disclosed a significant nonlinear dose-response relationship between dopamine agonists and frequency of ICD symptoms (P < 0.01). CONCLUSIONS: Impulse-control disorder symptoms were more frequent in the patients with PD than in the poststroke patients with PD. Impulse-control disorder symptoms were related to younger age and exposure to monoaminooxidase-B inhibitors, and showed a nonlinear dose-response relationship with dopamine agonists.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Lippincott Williams  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
AMANTADINE  
dc.subject
DOPAMINE AGONISTS  
dc.subject
IMPULSE-CONTROL DISORDERS  
dc.subject
MONOAMINOOXIDASE-B INHIBITORS  
dc.subject
PARKINSON DISEASE  
dc.subject.classification
Neurología Clínica  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with parkinson disease  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-05-22T12:08:17Z  
dc.journal.volume
35  
dc.journal.number
6  
dc.journal.pagination
261-265  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Philadelphia  
dc.description.fil
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Inserm; Francia  
dc.description.fil
Fil: Rey, María Verónica. Inserm; Francia  
dc.description.fil
Fil: Fabre, Nelly. No especifíca;  
dc.description.fil
Fil: Ory, Fabienne. No especifíca;  
dc.description.fil
Fil: Spampinato, Umberto. No especifíca;  
dc.description.fil
Fil: Brefel Courbon, Christine. No especifíca;  
dc.description.fil
Fil: Montastruc, Jean Louis. No especifíca;  
dc.description.fil
Fil: Rascol, Olivier. Inserm; Francia  
dc.journal.title
Clinical Neuropharmacology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://journals.lww.com/clinicalneuropharm/Abstract/2012/11000/Prevalence_and_Pharmacological_Factors_Associated.1.aspx  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1097/WNF.0b013e31826e6e6d